Hai-Xia Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hai-Xia Gao has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Xinxia Li
Department of Pathology, Xinjiang Medical University Affiliated Tumor Hospital, Urumqi, China
4 shared publications Gulinaer Abulajiang
Department of Pathology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region 830054, P.R. China
3 shared publicationsJing Niu
Department of Pathology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region 830054, P.R. China
3 shared publications- Jing Xue
Department of Pathology, The First Affiliated Hospital of Xinjiang Medical University, No. 137 Liyushan Southern Road, Urumqi, The Xinjiang Uygur Autonomous Region of China, 830054, PR China; Xinjiang Medical University, No. 393 Xinyi Road, Urumqi, The Xinjiang Uygur Autonomous Region of China, 830011, PR China
3 shared publications Wei Sang
Department of Pathology, The First Affiliated Hospital of Xinjiang Medical University, No. 137 Liyushan Southern Road, Urumqi, The Xinjiang Uygur Autonomous Region of China, 830054, PR China
3 shared publicationsWei Zhang
Department of Pathology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region 830054, P.R. China
3 shared publications
Latest Publications
- Open Access
- 1 July 2020
- Published by Springer Nature in Research Square
Screening and identifcation of differentially expressed microRNAs in diffuse large B-cell lymphoma based on microRNA microarray
We aimed to screen and identify differentially expressed microRNAs (miRNAs) between diffuse large B-cell lymphoma (DLBCL) and control (lymph node reactive hyperplasia, LRH) groups, investigate whether miRNAs associated with DLBCL and could serve as potential therapeutic targets. Five DLBCL experimental samples and five control samples were obtained from fresh tissues. The exclusion criteria were expressed as follows: patients with other lymphoid diseases and patients undergoing chemical treatment. Firstly, fresh samples were analyzed using microRNA microarray to identify differentially expressed miRNAs. Next, three databases (Targetscan, microRNAorg, PITA) were used to intersection predict the potential target gene of the 204 differential miRNAs and performed Venn diagram of the results. Then, target genes of differential miRNAs were performed by Gene ontology (GO) and Kyoto Encyclopedia of Gene and Genome (KEGG) pathway analysis. Finally, to validate the microRNA microarray data, we performed Real-time reverse transcription PCR (qRT-PCR) for eight differentially expressed miRNAs (miR-193a-3p, miR-19a-3p, miR-19b-3p, miR-370-3p, miR-1275, miR-490-5p, miR-630 and miR-665) using DLBCL and LRH fresh samples. Two hundred and four miRNAs showed differential expression, including 105 down-regulated and 54 up-regulated miRNAs. The cut-off criterion was set as P value ≤0.05 and fold change (FC) ≥2. A total of 7522 potential target genes for the 204 miRNAs were predicted. Potential target genes were enriched in pathway in cancers, MAPK signal pathway, regulation of actin cytoskeleton, focal adhesion, endocytosis, Wnt signal pathway, axon guidance, calcium signal pathway, and PI3K/AKT signal pathway. Eight miRNAs validation by qRT-PCR, four miRNAs (miR-19b-3p, miR-193a-3p, miR-370-3p and miR-490-5p) were low expression in DLBCL (P< 0.05). The high expression of miR-630 in DLBCL was statistically significant (P< 0.05). Our results of identification of differentially expressed miRNAs, predicted the target gene of the differential miRNAs, enrichment of target gene biological functions and signaling pathway, will provide basis for researchers in identifying the pathogenesis of DLBCL, could serve as reliable biomarkers for precise diagnosis and as therapeutic target for improvement of therapeutic efficacy in DLBCL in the future.
- 1 July 2020
- Published by Springer Nature in Research Square
Open AccessScreening and identifcation of differentially expressed microRNAs in diffuse large B-cell lymphoma based on microRNA microarray
We aimed to screen and identify differentially expressed microRNAs (miRNAs) between diffuse large B-cell lymphoma (DLBCL) and control (lymph node reactive hyperplasia, LRH) groups, investigate whether miRNAs associated with DLBCL and could serve as potential therapeutic targets. Five DLBCL experimental samples and five control samples were obtained from fresh tissues. The exclusion criteria were expressed as follows: patients with other lymphoid diseases and patients undergoing chemical treatment. Firstly, fresh samples were analyzed using microRNA microarray to identify differentially expressed miRNAs. Next, three databases (Targetscan, microRNAorg, PITA) were used to intersection predict the potential target gene of the 204 differential miRNAs and performed Venn diagram of the results. Then, target genes of differential miRNAs were performed by Gene ontology (GO) and Kyoto Encyclopedia of Gene and Genome (KEGG) pathway analysis. Finally, to validate the microRNA microarray data, we performed Real-time reverse transcription PCR (qRT-PCR) for eight differentially expressed miRNAs (miR-193a-3p, miR-19a-3p, miR-19b-3p, miR-370-3p, miR-1275, miR-490-5p, miR-630 and miR-665) using DLBCL and LRH fresh samples. Two hundred and four miRNAs showed differential expression, including 105 down-regulated and 54 up-regulated miRNAs. The cut-off criterion was set as P value ≤0.05 and fold change (FC) ≥2. A total of 7522 potential target genes for the 204 miRNAs were predicted. Potential target genes were enriched in pathway in cancers, MAPK signal pathway, regulation of actin cytoskeleton, focal adhesion, endocytosis, Wnt signal pathway, axon guidance, calcium signal pathway, and PI3K/AKT signal pathway. Eight miRNAs validation by qRT-PCR, four miRNAs (miR-19b-3p, miR-193a-3p, miR-370-3p and miR-490-5p) were low expression in DLBCL (P< 0.05). The high expression of miR-630 in DLBCL was statistically significant (P< 0.05). Our results of identification of differentially expressed miRNAs, predicted the target gene of the differential miRNAs, enrichment of target gene biological functions and signaling pathway, will provide basis for researchers in identifying the pathogenesis of DLBCL, could serve as reliable biomarkers for precise diagnosis and as therapeutic target for improvement of therapeutic efficacy in DLBCL in the future.
- Open Access
- 27 May 2020
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 22 (2) , 1243-1256
Prognostic value of MYD88 L265P mutation in diffuse large B cell lymphoma via droplet digital PCR
To assess the prevalence and prognostic value of myeloid differentiation factor 88 (MYD88) expression and mutational status in diffuse large B cell lymphoma (DLBCL), a total cohort of 100 patients with DLBCL were studied using immunohistochemistry (IHC) and droplet digital polymerase chain reaction (DDPCR), and the association between MYD88 expression and clinicopathological parameters was analyzed. Overall, the positive expression rate of MYD88 protein was 38% and the gene mutation rate was 29%. The positive expression and mutation rates were the highest in the primary central nervous system lymphomas (58.33 and 66.67%, respectively). The coincidence rate of the results of MYD88 expression between IHC and DDPCR results was 73% (73/100). Univariate survival analysis showed that age (≥60 years old), high neutrophil/lymphocyte count ratio, low lymphocyte count, c‑Myc ≥40%, positive MYD88 protein expression, and gene mutation were associated with poorer prognosis rates. Multivariate survival analysis revealed that MYD88 expression was an independent prognostic factor affecting overall survival. In conclusion, the results of this study demonstrated that MYD88 mutation was a valuable index to evaluate the prognosis of DLBCL. DDPCR can be used as a method for detecting MYD88 mutations, although it was not completely consistent with the results of IHC.
- 27 May 2020
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 22 (2) , 1243-1256
Open AccessPrognostic value of MYD88 L265P mutation in diffuse large B cell lymphoma via droplet digital PCR
To assess the prevalence and prognostic value of myeloid differentiation factor 88 (MYD88) expression and mutational status in diffuse large B cell lymphoma (DLBCL), a total cohort of 100 patients with DLBCL were studied using immunohistochemistry (IHC) and droplet digital polymerase chain reaction (DDPCR), and the association between MYD88 expression and clinicopathological parameters was analyzed. Overall, the positive expression rate of MYD88 protein was 38% and the gene mutation rate was 29%. The positive expression and mutation rates were the highest in the primary central nervous system lymphomas (58.33 and 66.67%, respectively). The coincidence rate of the results of MYD88 expression between IHC and DDPCR results was 73% (73/100). Univariate survival analysis showed that age (≥60 years old), high neutrophil/lymphocyte count ratio, low lymphocyte count, c‑Myc ≥40%, positive MYD88 protein expression, and gene mutation were associated with poorer prognosis rates. Multivariate survival analysis revealed that MYD88 expression was an independent prognostic factor affecting overall survival. In conclusion, the results of this study demonstrated that MYD88 mutation was a valuable index to evaluate the prognosis of DLBCL. DDPCR can be used as a method for detecting MYD88 mutations, although it was not completely consistent with the results of IHC.
- 1 February 2020
- Published by Elsevier in Pathology - Research and Practice
- Vol. 216 (2) , 152799
TCL1 as a hub protein associated with the PI3K/AKT signaling pathway in diffuse large B-cell lymphoma based on proteomics methods
- 1 February 2020
- Published by Elsevier in Pathology - Research and Practice
- Vol. 216 (2) , 152799
TCL1 as a hub protein associated with the PI3K/AKT signaling pathway in diffuse large B-cell lymphoma based on proteomics methods
- Open Access
- 2 October 2019
- Published by Spandidos Publications in Oncology Letters
- Vol. 18 (6) , 6033-6045
Identification of core differentially methylated genes in glioma
Differentially methylated genes (DMGs) serve a crucial role in the pathogenesis of glioma via the regulation of the cell cycle, proliferation, apoptosis, migration, infiltration, DNA repair and signaling pathways. This study aimed to identify aberrant DMGs and pathways by comprehensive bioinformatics analysis. The gene expression profile of GSE28094 was downloaded from the Gene Expression Omnibus (GEO) database, and the GEO2R online tool was used to find DMGs. Gene Ontology (GO) functional analysis and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis of the DMGs were performed by using the Database for Annotation Visualization and Integrated Discovery. A protein-protein interaction (PPI) network was constructed with Search Tool for the Retrieval of Interacting Genes. Analysis of modules in the PPI networks was performed by Molecular Complex Detection in Cytoscape software, and four modules were performed. The hub genes with a high degree of connectivity were verified by The Cancer Genome Atlas database. A total of 349 DMGs, including 167 hypermethylation genes, were enriched in biological processes of negative and positive regulation of cell proliferation and positive regulation of transcription from RNA polymerase II promoter. Pathway analysis enrichment revealed that cancer regulated the pluripotency of stem cells and the PI3K-AKT signaling pathway, whereas 182 hypomethylated genes were enriched in biological processes of immune response, cellular response to lipopolysaccharide and peptidyl-tyrosine phosphorylation. Pathway enrichment analysis revealed cytokine-cytokine receptor interaction, type I diabetes mellitus and TNF signaling pathway. A total of 20 hub genes were identified, of which eight genes were associated with survival, including notch receptor 1 (NOTCH1), SRC proto-oncogene (also known as non-receptor tyrosine kinase, SRC), interleukin 6 (IL6), matrix metallopeptidase 9 (MMP9), interleukin 10 (IL10), caspase 3 (CASP3), erb-b2 receptor tyrosine kinase 2 (ERBB2) and epidermal growth factor (EGF). Therefore, bioinformatics analysis identified a series of core DMGs and pathways in glioma. The results of the present study may facilitate the assessment of the tumorigenicity and progression of glioma. Furthermore, the significant DMGs may provide potential methylation-based biomarkers for the precise diagnosis and targeted treatment of glioma.
- 2 October 2019
- Published by Spandidos Publications in Oncology Letters
- Vol. 18 (6) , 6033-6045
Open AccessIdentification of core differentially methylated genes in glioma
Differentially methylated genes (DMGs) serve a crucial role in the pathogenesis of glioma via the regulation of the cell cycle, proliferation, apoptosis, migration, infiltration, DNA repair and signaling pathways. This study aimed to identify aberrant DMGs and pathways by comprehensive bioinformatics analysis. The gene expression profile of GSE28094 was downloaded from the Gene Expression Omnibus (GEO) database, and the GEO2R online tool was used to find DMGs. Gene Ontology (GO) functional analysis and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis of the DMGs were performed by using the Database for Annotation Visualization and Integrated Discovery. A protein-protein interaction (PPI) network was constructed with Search Tool for the Retrieval of Interacting Genes. Analysis of modules in the PPI networks was performed by Molecular Complex Detection in Cytoscape software, and four modules were performed. The hub genes with a high degree of connectivity were verified by The Cancer Genome Atlas database. A total of 349 DMGs, including 167 hypermethylation genes, were enriched in biological processes of negative and positive regulation of cell proliferation and positive regulation of transcription from RNA polymerase II promoter. Pathway analysis enrichment revealed that cancer regulated the pluripotency of stem cells and the PI3K-AKT signaling pathway, whereas 182 hypomethylated genes were enriched in biological processes of immune response, cellular response to lipopolysaccharide and peptidyl-tyrosine phosphorylation. Pathway enrichment analysis revealed cytokine-cytokine receptor interaction, type I diabetes mellitus and TNF signaling pathway. A total of 20 hub genes were identified, of which eight genes were associated with survival, including notch receptor 1 (NOTCH1), SRC proto-oncogene (also known as non-receptor tyrosine kinase, SRC), interleukin 6 (IL6), matrix metallopeptidase 9 (MMP9), interleukin 10 (IL10), caspase 3 (CASP3), erb-b2 receptor tyrosine kinase 2 (ERBB2) and epidermal growth factor (EGF). Therefore, bioinformatics analysis identified a series of core DMGs and pathways in glioma. The results of the present study may facilitate the assessment of the tumorigenicity and progression of glioma. Furthermore, the significant DMGs may provide potential methylation-based biomarkers for the precise diagnosis and targeted treatment of glioma.
- 1 September 2019
- Published by Elsevier in Pathology - Research and Practice
- Vol. 215 (9) , 152528
Quantitative proteomics analysis of differentially expressed proteins in activated B-cell-like diffuse large B-cell lymphoma using quantitative proteomics
- 1 September 2019
- Published by Elsevier in Pathology - Research and Practice
- Vol. 215 (9) , 152528
Quantitative proteomics analysis of differentially expressed proteins in activated B-cell-like diffuse large B-cell lymphoma using quantitative proteomics
- 15 February 2014
- Vol. 7 (3) , 1258-65
Parachordoma/myoepithelioma of the kidney: first report of a myxoid mimicry in an unusual location.
We report a case of parachordoma (or myoepithelioma) of the right upper kidney in a 56 year-old male patient. Light microscopic features of the tumor exhibited epithelioid, glomoid, and spindle cells with eosinophilic and vacuolated cytoplasm as well as round to oval nuclei. These cells were embedded in a myxoid and hyaline stroma separated by a fibrous tissue with minimal cellular atypia and a few small nucleoli. Immunohistochemically, the tumor cells were immunoreactive for epithelial membrane antigen, calponin, vimentin, S-100, and type-IV collagen. All kidney and adrenal were resected, and the patient was carefully followed up. During the 11 months follow-up, recurrence and metastases were not observed. To our knowledge, this study is the first to document a case of parachordoma/myoepithelioma of the kidney. We add this new case to existing tumors and discuss its distinction from other types.
- 15 February 2014
- Vol. 7 (3) , 1258-65
Parachordoma/myoepithelioma of the kidney: first report of a myxoid mimicry in an unusual location.
We report a case of parachordoma (or myoepithelioma) of the right upper kidney in a 56 year-old male patient. Light microscopic features of the tumor exhibited epithelioid, glomoid, and spindle cells with eosinophilic and vacuolated cytoplasm as well as round to oval nuclei. These cells were embedded in a myxoid and hyaline stroma separated by a fibrous tissue with minimal cellular atypia and a few small nucleoli. Immunohistochemically, the tumor cells were immunoreactive for epithelial membrane antigen, calponin, vimentin, S-100, and type-IV collagen. All kidney and adrenal were resected, and the patient was carefully followed up. During the 11 months follow-up, recurrence and metastases were not observed. To our knowledge, this study is the first to document a case of parachordoma/myoepithelioma of the kidney. We add this new case to existing tumors and discuss its distinction from other types.